meningococcal infections/nauzea

Odkaz sa uloží do schránky

Vyberte typ zoradenia

9 výsledky

Presenting features of meningococcal disease, public health messages and media publicity: are they consistent?

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To investigate whether the presenting features of meningococcal disease as promoted in public health awareness material and in the print media accurately reflect the clinical features in patients admitted to Auckland hospitals with meningococcal disease January 1998 to June

[Clinical characterization of cases with meningococcal disease by W135 group in Chile, 2012].

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND During 2012 in Chile, there were 60 cases of serogroup W135 meningococcal disease, which accounts for 57.7% of identified serogroup cases. OBJECTIVE To describe main clinical features of patients with serogroup W135 meningococcal disease confirmed in 2012. METHODS Descriptive study of

[Gastrointestinal symptoms with meningococcal infection. Emergence of Neisseria meningitidis serogroup W.]

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND Meningococcal disease usually presents as meningitis and/or septicaemia, but can also present as pneumonia or arthritis. Since 2000, a worldwide increase in meningococcal disease is reported which is caused by a new virulent clone of serogroup W (MenW:cc11). This subtype is more likely to

Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Atypical clinical presentations associated with group W meningococcal disease (MenW) are well-described and include pneumonia, septic arthritis, endocarditis and epiglottitis/supraglottitis. Following anecdotal reports of teenagers presenting with predominantly gastrointestinal symptoms, we

Notes from the Field: Meningococcal Disease in an International Traveler on Eculizumab Therapy - United States, 2015.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

On June 2, 2015, CDC was notified that a male airline passenger, aged 41 years, with a fever of 105.4°F, headache, nausea, photophobia, diarrhea, and vomiting, which began approximately 3 hours after departure, was arriving to San Francisco, California, on a flight from Frankfurt, Germany. His

Disseminated Gonococcal Infection Associated with Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria: A Case Report and Literature Review

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Eculizumab has been developed as a breakthrough treatment for paroxysmal nocturnal hemoglobinuria (PNH). Not only for breakthroughs, eculizumab therapy is also known to increase the risk of invasive meningococcal infection. It has also been recently reported that, although rarely, administration of

Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Background: Four-component meningococcal B (4CMenB) vaccine is licensed in many countries but has had limited use in adolescents despite this age group being at increased risk of meningococcal disease.

Minocycline for prophylaxis of infection with Neisseria meningitidis: high rate of side effects in recipients.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia

A high rate of side effects (mostly vestibular) was found among 83 people receiving prophylaxis with minocycline because of contact with a patient who had died of meningitis due to Neisseria meningitidis. Three groups of contacts received different lots of minocycline and different dosage regimens.

Eculizumab.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia

OBJECTIVE The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of eculizumab are reviewed. CONCLUSIONS Eculizumab, a recombinant, humanized, monoclonal, immunoglobulin G antibody produced from murine myeloma cells, is

Pripojte sa k našej
facebookovej stránke
Herbal & Natural Medicine
Najkompletnejšia databáza liečivých bylín podporovaná vedou
Pracuje v 55 jazykoch
Bylinné lieky podporené vedou
Rozpoznávanie bylín podľa obrázka
Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
Vyhľadajte liečivé byliny podľa ich účinkov
Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi
Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume